SCOLR Pharma Announces Completion Of Patient Enrollment And Dosing For Pivotal Clinical Trial Evaluating Extended Release Ibuprofen SCOLR Pharma, Inc. (Amex: DDD) announced the completion of patient enrollment and dosing for the third of its three pivotal trials to evaluate the safety and efficacy of its formulation of 12-hour extended-release (ER) ibuprofen for the over-the-counter (OTC) market. The Company expects to report top-line results from this pivotal trial in November 2008.
Source: www.medicalnewstoday.comMedia Statement From Servier: High Court Of Justice Judgment Awarding Damges To Apotex Servier is disappointed by the decision of the English High Court (Mr Justice Norris) to award damages to Apotex of GBP17.5 million in the case of Les Laboratoires Servier vs Apotex Inc. Servier is currently considering whether to appeal the Judgment. However, Servier acknowledges that Mr Justice Norris's Judgment rejected Apotex's original claim for GBP27 million and awarded it a substantially reduced amount (GBP17.5 million).
Source: www.medicalnewstoday.com
# posted by Network @ 8:00 AM
